Prevalence of Metabolic Syndrome in Gout Patients and Its Relationship With Metabolic Markers: A Propensity Score Matching Study
International Journal of Rheumatic Diseases · 2025
DOI: 10.1111/1756-185x.70424 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2025. Verfasst von Wanping Lv und 4 weiteren Autor:innen. Beteiligte Einrichtung: Outpatient Department, Chengdu Rheumatology Hospital, Chengdu, China. Hauptthemen laut MEDLINE: Gout, Metabolic Syndrome, Triglycerides. Die Arbeit nennt 46 Literaturangaben. Gefördert von: the Special Project for Traditional Chinese Medicine Research of Sichuan Provincial Administration of Traditional Chinese Medicine, Chengdu Medical Research Project.
Abstract (Originalsprache)
Objective
To evaluate the association between metabolic markers and metabolic syndrome (MetS) in gout patients, and to assess the predictive performance of the triglyceride‐glucose (TyG) index and triglyceride/high‐density lipoprotein cholesterol (THR) ratio.
Methods
In this cross‐sectional study, 502 gout patients (97.8% male) admitted between February 2023 and February 2024 were enrolled. MetS was defined according to the International Diabetes Federation criteria. Four metabolic markers—TyG, THR, serum uric acid/creatinine (SUA/Cr) ratio, and C‐reactive protein/HDL‐C ratio—were measured. Multivariate logistic regression identified independent predictors of MetS, while receiver operating characteristic (ROC) curves evaluated diagnostic accuracy. Propensity score matching and restricted cubic spline analyses were also performed to adjust for confounders and explore dose–response relationships.
Results
The prevalence of MetS was 62.4%. Patients with MetS exhibited significantly higher weight, systolic blood pressure (SBP), TyG, and THR values compared to non‐MetS subjects (all p < 0.05). After adjustment, TyG (OR = 3.94, 95% CI: 2.60, 5.98) and THR (OR = 1.66, 95% CI: 1.33, 2.07) remained independently associated with MetS. ROC analysis revealed AUCs of 0.771 for TyG and 0.776 for THR; a combined model achieved an AUC of 0.820. A non‐linear dose–response relationship was also observed.
Conclusion
Elevated TyG and THR indices are robust, independent predictors of MetS in gout patients. These cost‐effective markers may facilitate early screening and risk stratification in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Outpatient Department, Chengdu Rheumatology Hospital, Chengdu, China.
- Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- Hospitalization Department, Zhengzhou Gout and Rheumatology Hospital, Zhengzhou, China.
- School of Clinical Medicine, Zhengzhou University, Zhengzhou, China.
- Department of Rheumatology and Immunology, Guiyang Qiangzhi Hospital, Guiyang, China.
- Department of Rheumatology and Immunology, Harbin Ankylosing Rheumatology Hospital, Harbin, China.
ORCID-Profile: Yu Lei
Förderung
- the Special Project for Traditional Chinese Medicine Research of Sichuan Provincial Administration of Traditional Chinese Medicine
- Chengdu Medical Research Project
Zitieren
APA
Lv, W., Chen, H., Zhu, H., Han, D., & Lei, Y. (2025). Prevalence of Metabolic Syndrome in Gout Patients and Its Relationship With Metabolic Markers: A Propensity Score Matching Study. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70424
Vancouver
Lv W, Chen H, Zhu H, Han D, Lei Y. Prevalence of Metabolic Syndrome in Gout Patients and Its Relationship With Metabolic Markers: A Propensity Score Matching Study. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70424
BibTeX
@article{Lv2025,
author = {Lv, Wanping and Chen, Huixiang and Zhu, Hongmei and Han, Dong and Lei, Yu},
title = {Prevalence of Metabolic Syndrome in Gout Patients and Its Relationship With Metabolic Markers: A Propensity Score Matching Study},
journal = {International Journal of Rheumatic Diseases},
year = {2025},
doi = {10.1111/1756-185x.70424}
}
EUVIMED